Compare Campbell Soup Co. (CPB) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Crispr Therapeutics AG — how do they compare? Campbell Soup Co. trades at $22.71 (market cap $6.78B), while Crispr Therapeutics AG trades at $54.08 (market cap $5.23B). The key difference: Campbell Soup Co. is the larger of the two by market cap, and Campbell Soup Co. pays a 6.87% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CPB | CRSP | |
|---|---|---|
Market Cap | $6.78B | $5.23B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $76.78 |
52-Week Low | $20.00 | $44.34 |
Enterprise Value | $13.38B | $3.65B |
Dividend Yield | 6.87% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
